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Influence of uremia and hemodialysis on circulating
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Influence of uremia and hemodlalysis on circulating interleukin-1 and
tumor necrosis factor a. Interleukin-1 (IL-I) and tumor necrosis factor
a (TNFa) were determined in the plasma of long-term hemodialysis
(HD) patients and uremic (UR) patients undergoing their first dialysis
session using either cellulosic (CUP) or synthetic (PAN-AN 69) mem-
brane-equipped dialyzers. In long-term HD patients, plasma IL-I and
TNFa levels were significantly increased compared to their levels in
normal subjects. During a single dialysis session, a significant increase
in IL-I but not in TNFa was observed. In not yet dialyzed UR patients,
LL-l plasma levels did not differ from those observed in normal
subjects. By contrast, TNFa was found significantly increased although
less than in long-term HD patients. During the first dialysis session, no
significant increase was observed in the levels of either monokine,
Lastly, regardless of the group of patients, no significant influence of
the dialysis membrane could be detected, suggesting that the observed
changes are not exclusively secondary to the activation of complement.
Altogether, these results suggest that the passage of the blood through
the extracorporeal dialysis circuit triggers the secretion of IL-i and
further exacerbates that of TNFa by monocytes. The presence of
increased TNFa in the plasma of first-dialysis UR patients suggests that
factors unrelated to dialysis contribute to the activation of monocytes in
these patients. Lastly, the concomitant presence of IL-I and TNFa in
the plasma of long-term HD patients could be responsible for some of
the clinical features observed in these patients, and provides strong
evidence favoring the concept that HD can be assimilated to a recurrent
acute-phase inflammatory response.
Growing interest has focused in recent years on the role of
cytokines in relation to the acute phase response of the inflam-
matory process [1—3]. Among these cytokines, interleukin-1
(IL-i), which is mainly derived from monocyte-macrophages,
has been shown to exert a broad range of activities associated
with both acute and chronic inflammatory changes [4, 5], and to
possess distinct and multiple biological properties recently
confirmed by molecular cloning [6].
As early as 1983, Henderson et al [7] postulated that IL-l may
be involved in some of the acute and chronic secondary effects
of long-term hemodialysis (HD) treatment. However, the actual
immunopathological role of IL-i in HD patients is just begin-
ning to be investigated [8—10].
Another monokine that may well be relevant in HD-induced
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pathology symptoms is the tumor necrosis factor a (TNFa) [3,
11]. Although TNFa and IL-i are biochemically and immuno-
logically distinct, they share remarkable similarities in their
biological properties [12, 13]. The fact that both monokines
exert pleiotropic activities affecting distinct organs [14] along
with the observation that they can circulate in the blood, could
suggest that they be considered as hormones of inflammation [3,
4]. Lastly, TNFa is able to induce the production of IL-i in vivo
and in vitro [15], and a synergy between the two monokines has
also been shown in vivo during inflammation [16] and septic
shock [171. To our knowledge, TNFa has not been extensively
investigated in long-term HD patients [18], whereas more
consistent studies have been reported in acute clinical situa-
tions such as severe septicemia [19] or renal allograft rejection
[201.
It has also long been documented that uremia can itself impair
the immune response capacity, as has been shown both in
patients with end-stage renal failure [21] and in experimental
uremia models in the rabbit [22, 23]. Most of these studies have
focused on T cell-mediated reactions [241, or on neutrophil and
monocytic functions such as chemotactic, adherence, phago-
cytic or bactericidal activities in order to explain the high
susceptibility of uremic patients to infections [25—27]. How-
ever, the possibility that terminal renal failure could also result
in monocyte activation leading to monokine production has not
yet been investigated.
Among the dialysis-related factors which can result in mono-
cyte alteration and/or activation, the cellulosic nature of the
dialysis membrane has been incriminated [28—30], mainly via its
capacity to activate complement system. In this regard, we
previously showed both in vivo and in vitro that cellulosic
cuprophane (CUP) but not synthetic polyacrilonitrile (PAN-AN
69) dialysis membrane leads to a strong activation of phagocyte
oxidative metabolism which is detectable within whole blood
and is, at least partly, induced by activated complement com-
ponents generated in the plasma following blood interaction
with the membrane [31].
In 1986, we first reported a preliminary study showing that
plasma IL- 1 is significantly increased in long-term HD patients
and that this elevation occurred regardless of the nature of the
dialysis membrane [8]. Furthermore, the capacity of monocytes
to release IL-i on contact with dialysis membranes has also
been observed in vitro and even in the absence of complement
[32].
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The present study attempts to determine the respective
influence of hemodialysis and uremia on circulating IL-I and
TNFa and to evaluate the influence of the nature of the dialysis
membrane on the presence of these monokines. For this pur-
pose, plasma from both first-dialysis UR and long-term HD
patients have been investigated at the start and at the end of the
dialysis session, using either CUP or PAN-AN 69 membranes.
Methods
Patients and control subjects
Forty-four patients with end-stage renal failure, including 18
males and 22 females ranging in age from 21 to 69 years (mean
50.1 years), participated in the study upon informed consent.
Twenty-six of them were long-term hemodialyzed (HD) pa-
tients (46 9 months, mean suM), undergoing from four to
five hours of maintenance thrice a week. Eighteen uremic
patients (UR) not yet dialyzed were tested just before and
during their first dialysis session. The etiology of renal failure
did not differ greatly from that of the general dialysis population
(glomerulonephritis, 15; polycystic kidney disease, 8; renal
vascular disease, 6; hereditary nephropathy, 5; and unknown
etiology, 10). Inclusion criteria were the absence of intercurrent
infection and/or immunosuppressive therapy.
Two types of dialyzers of comparable surface (1 to 1.4 m2)
were used: a disposable plate kidney equipped with synthetic
polyacrilonitrile (PAN-AN 69 membrane, Hospal, Meysieu,
France) and a kidney equipped with cellulosic cuprophane
capillary membrane (CUP, Hospal). All long-term HD patients
were dialyzed with the same type of membrane for at least three
months. Acetate baths were used in all patients except two who
were dialyzed with bicarbonate baths.
Twenty-five healthy subjects recruited among volunteer
blood donors served as controls.
Plasma preparation
Patient blood samples of 15 ml were collected in heparinized
tubes (Liquemine Roche, Paris, France, 10 U/mI of blood) from
the arterial site of the arteriovenous fistula at the start and at the
end of dialysis sessions. In normal subjects, blood samples
were obtained by cubital venous puncture.
Blood samples were centrifuged (600 X g, 10 mm). The
plasma was separated into small aliquots and frozen at —70°C
and all assays were carried out on samples thawed only once. In
order to remove inhibitory factors, plasma were gel filtrated
before testing for IL-i according to the methodology first
proposed by Cannon and Dinareilo [331 and also used by other
groups [8, 9]. Briefly, 0.3 ml of plasma was applied to a I x 30
cm sterile column with packed autoclaved Sephadex 0-50 fine
(Pharmacia Fine Chemicals, Uppsala, Sweden). The column
was equilibrated with RPM! 1640 medium (Gibco Laboratories,
Grand Island, New York, USA) supplemented with 25 mM
Hepes (Gibco), 2 mri L-glutamine (Gibco), 100 lU/mi penicillin
(Gibco), 100 pg/ml streptomycin (Gibco), and 5 X iO M
2-mercaptoethanol (2-ME, Merck, Darmstadt, FRG). Thirty-
two 0.7 ml fractions were collected in sterile, pyrogen-free
polypropylene tubes at a flow rate of 1 mI/mm.
Cytokines
Human IL-i (hu IL-i), purified from monocyte supernatant,
was purchased from Genzyme (Suffolk, England, UK). Recom-
binant human TNFa (hu rTNF), recombinant human IL-1/3 (hu
rIL-1.3) and recombinant human IL-la (hu rIL-la) were from
Dr. F. Floc'h, (Rhône Poulenc, Vitry, France). Based on
half-maximal PHA-induced thymocyte stimulation, 1 U/mI of
hu rIL-13 preparation corresponds to 100 pg/mi as defined by
immunodetection (ELISA, Cistron Biotechnology, Pine Brook,
New Jersey, USA). The activity of recombinant human inter-
leukin-2 (hu rIL-2), provided by the Sandoz Forschunginstitut,
Vienna, Austria, was calculated based on the NIH standard.
Recombinant munne interleukin-4 (mu rIL-4), of Dr. F.
Melchers (Basel Institute for Immunology, Basel, Switzerland),
was provided by Dr. E. Ruuth [34], and recombinant human
IL-4 (hu rIL-4) was provided by Dr. J. Banchereau (Unicet,
Dardilly, France). The effects of mu rIL-4 and hu rIL-4 in the
LAF assay were tested by adding twofold serial dilutions of
IL-4 to the thymocytes starting at concentrations far above the
optimal concentration determined in their respective assay.
Recombinant human interieukin-6 (hu rIL-6, Janssen Biochem-
ica, Beerse, Belgium) was from the Institut Henri Beaufour
(Les Ulis, France).
Bioassays for cytokines
The lymphocyte activating factor (LAF) assay. IL-i activity
was determined by measuring the augmentation of phytohemag-
glutinin (PHA)-induced murine thymocyte proliferation, as de-
scribed [35]. Briefly, io thymocytes obtained from lipopolysac-
charide-low responder C3H/HeJ mice, at four to six weeks of
age, (C.S.E.A.L. Orleans, France) were incubated in RPM!
1640 medium supplemented with 5% heat-inactivated fetal calf
serum (FCS, Flow Laboratories Limited, Irvine, Scotland,
UK), 25 mi Hepes, 2 mri L-glutamine, 100 lU/mi penicillin
(Gibco), 100 sg/mi streptomycin (Gibco), 5 X i0 M 2-ME, 1
pg/ml of PHA (Weilcome Research Laboratories, Beckenham,
England, UK), and plasma samples. Each plasma sample was
tested in triplicate. DNA synthesis was assayed for the last
eight hours of a 72 hour incubation at 37°C under 5% CO2
atmosphere by pulsing the cultures with 1 pCi/well of [3H1-
thymidine ([3H]-TdR, 5 Ci/mmol, Centre d'Energie Atomique,
Saclay, France). The standard deviation of triplicate samples
was less than 15% of the mean. Since responsiveness to both
PHA and IL-i varied among thymocyte preparations, pre- and
post-dialysis plasma fractions were assayed on the same thy-
mocyte population. IL-l activity in plasma fractions was ex-
pressed as a costimulation index (CI) defined by the mean of
triplicate determination of [3H]-TdR incorporation in each
eluted fraction, divided by the mean background incorporation
in the presence of fractions eluting before the void volume.
To discriminate the optimal fractions corresponding to IL-i
elution, normal plasma supplemented with various concentra-
tions of hu rIL-1/3 was subjected to gel filtration. A single peak
of IL-i activity eluting approximately 12,000 to 18,000 daltons
was detected. Based on these findings, all plasma from patients
and controls were fractionated and the 12,000 to 18,000 dalton
range fractions were tested for their LAF(IL- 1) activity. Plasma
IL-i level was expressed as the mean activity of these fractions.
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The detection limit of hu rIL-1f3 added to plasma and sub-
jected to gel filtration was 15 pg/mi, corresponding to a CI of
1.8. Fifty pg/mi of hu rIL- 113 gave a significant index of 4, and
1 pg of hu rIL-1/3 corresponds to approximately 0.12 CI.
In addition to IL- 1, the possible participation of IL-2, IL-4 or
IL-6, known to mediate thymocyte proliferation 135—37] in the
LAF assay, was investigated. In the presence of 1 tg/ml of
PHA (that is, the concentration used for detecting IL-i activi-
ty), no significant increase in thymocyte proliferation could be
detected with hu rIL-6 up to 12,500 U/mi. By contrast, and as
already described by other groups, significant increase in LAF
activity was observed upon addition of hu rIL-6 together with
10 jig/mi of PHA. As reported by Ziotnik et al [36], we also
found that murine rIL-4 induced significant LAF activity.
However, in our test conditions this LAP activity could not be
induced with human rIL-4, regardless of the concentration
used, thus confirming its species-specificity [38]. Lastly, plasma
fractions were tested for their IL-2 activity by the CTLL assay.
In some experiments, plasma IL-i activity was confirmed by
neutralization with an antibody against human IL-i (rabbit
polyclonal antibody, Cistron Biotechnology). In these experi-
ments, plasma fractions with significant IL-i activity were
incubated for six hours at 37°C with 2% to 0.25% (vollvol) rabbit
antibody or normal rabbit serum (as control) and then tested in
the LAF assay. In these conditions, we found that this anti-
body, when used at 2% (voL1vol), inhibited 90% of the biological
activity mediated by 80 pg of hu rIL- 1/3. This neutralization was
observed as well with chromatographed plasma supplemented
with hu rIL-la, hu rIL-i/3 or hu IL-i. In addition, this poly-
clonal anti-IL-i was tested for its effect on hu rIL-6-mediated
thymocyte proliferation and no significant inhibition could be
detected.
The TNFx activity assay. TNFa was measured by its cy-
tolytic activity on the L929 tumor cell line [39]. L929 cells were
maintained in RPM! 1640 medium supplemented with antibiot-
ics and 10% FCS. For the assay, cells were treated with trypsin
(0.125%) (Gibco), washed twice with RPMI and adjusted to a
density of 2.5 x l05/ml. The cells were seeded in 96-well
flat-bottomed culture plates (Falcon 3072, Becton-Dickinson
and C°, New Jersey, USA) at a density of 2.5 x 104/well and
incubated 24 hours at 37°C under 5% CO2 atmosphere in 100 jil
medium consisting of RPM! 1640 supplemented with antibiotics
and 10% FCS. The supernatant was eliminated and replaced by
75 ji! ofdiluted plasma supplemented with 75 jil of actinomycin
D (1 jig/mi; Behring Diagnostics, La Jolla, California, USA),
and the plate was further incubated for 18 hours.
Cytotoxicity was measured by the MTT (dimethyl-thiazol-
2-yl diphenyltetrazolium bromide, Sigma Chemical Co., St.
Louis, Missouri, USA) colorimetric assay [401 at 570 nm using
a microplate reader (MR 600, Dynatech, Alexandria, Virginia,
USA) with a reference filter at 630 nm. Plasma samples were
tested in duplicate and results of optical density of the sample
well as a percentage of that of the control well was taken as a
measure of cell survival. RPM! 1640 supplemented with 10%
FCS was used in the control wells. The amount of TNFa of
each plasma sample was calculated on the basis of dilution
curves plotted against cell survival. One TNFa unit was defined
as the amount of TNFa giving 50% cell survival. Before testing,
plasma samples were heated at 56°C for 30 minutes. The
detection limit of TNFa in plasma was about 10 U/mI cone-
sponding to a concentration of hu rTNFa of 28 pg/ml. It was
controlled that addition of up to 15% plasma had no effect on
the TNF cytolytic assay.
The bioassay for IL-2. The plasma fractionated samples were
tested for their ability to maintain the growth of an IL-2-
dependent murine T-cell line (CTLL), as described [35].
Briefly, cells were adjusted to a density of io cells/mi in RPM!
1640 medium containing antibiotics and 5% FCS. A total of i0
cells/well of a 96-well plate (Falcon) were incubated at 37°C in
5% CO2 for 48 hours with various sample concentrations. Cells
were pulsed for the final eight hours with [3H]-TdR and har-
vested as already described above. Recombinant human IL-2,
titrated along with the unknown samples, was used as positive
control.
Immunoassays for cytokines
Enzyme-linked immunosorbent assay (ELISA) for IL-I /3. A
commercial, enzyme-linked immunosorbent assay (ELISA,
Cistron Biotechnology) was used according to the manufactur-
er's suggestions for measuring IL-i/3 levels in diluted plasma
samples. The antiserum in this assay was shown to be specific
for IL-l /3, and the lowest concentration of hu rIL- 1/3 detectable
from the zero level was 15 to 20 pg/mI. Samples below the
detection level of 15 pg/mi were assumed to have a value of 7.5
pg/mi, that is, the midpoint of the interval between 0 and 15.
Radioimmunoassays (RIA). A commercial radioimmunoas-
say (RIA, Cistron Biotechnology), which was standardized with
hu rIL-1f3, was used for measuring IL-l/3 levels in diluted
plasma samples. Previous experiments to validate the immu-
noassay showed a detection limit of 250 pg/mI for hu rIL- 1/3 in
plasma, less than 10% interassay variation and more than 80%
recovery in the detection of recombinant IL-1/3 added to plasma
regardless of plasma origin (control subjects, HD or UR pa-
tients).
TNFa, IL-2 and gamma interferon (IFNy) were assessed in
the plasma of patients and controls by means of soluble phase
RIA (Prof. P. Franchimont, University of Liege, Belgium) and
IRE-MEDGENIX (Fleurus, Belgium), using specific rabbit
polyclonal antisera and iodinated human recombinant cytokine
molecules as described in [41, 42]. The sensitivities of the RIA
used, defined as the smallest amount of unlabelled antigen able
to significantly reduce the binding of the corresponding cyto-
kine to each given specific antibody, were as follows: 50 pg/mi
for TNFa, 0.4 U/mI for IFNy and 0.5 U/mi for IL-2. As already
detailed elsewhere [41, 42] the antiserum used in each RIA did
not show cross reactivities that could affect the specificity of the
assays in the experimental conditions used.
Presentation of results and statistical analysis
In long-term HD patients, each post-hemodialysis cytokine
plasma level was corrected according to hemoconcentration
measurement using the method described by Bergstrom and
Wehle [43]. Such correction was not made in nondialyzed UR
patients undergoing their first dialysis since no ultrafiltration
was performed.
All data are given as mean SEM and compared either by the
Student's 1-test or by the paired 1-test depending on the sample
groups (unpaired or paired) to be compared. Differences were
considered to be significant when P was less than 0.05.
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Fig. 1. Plasma IL-I activity in 25 healthy control subjects (C), 13
first-dialysis uremic patients (UR) and 25 long-term heinodialysis
patients (HD) before a dialysis session. Each point represents the mean
of IL-i activity (CI) in plasma fractions ranging from 12 to 18 kDa
molecular mass, obtained in a given patient. Plasma IL-I activity is
significantly increased in HD patients, compared both to healthy
control subjects and UR patients (P < 0.001).
Results
Plasma LAF(IL-I) activity
Comparison between first dialysis and long-term dialysis
patients. Figure 1 compares the LAF(IL-l) activity observed in
plasma fractions from 13 UR patients undergoing their first
dialysis session, 25 long-term HD patients and 25 normal
subjects. All patients were tested at the start of the dialysis
session. Compared to normal subjects (CI: 1.05 0.08, mean
5EM), no significant LAF(IL-l) activity was detected in plasma
fractions from UR patients (CI: 1.27 0.07, mean SEM). By
contrast, and although great variations existed among individ-
ual cases, the mean LAF(IL-l) activity was significantly higher
in HD patients (CI: 2.91 0.30, mean SEM; P <0.001). The
results obtained in control normal subjects show that a signifi-
cant IL-i activity gives a CI superior to 1.8 (mean + 2 SD of
controls). According to data obtained with normal plasma
supplemented with hu rIL-1/3, this CI corresponded to approx-
imately 15 pg/mi of IL-i. On this basis, significant LAF(IL- 1)
activity was found in 1 out of 25 control subjects and I out of 13
UR first-dialysis patients against 20 out of 25 long-term HD
patients (P < 0.001; test). Among the latter, four patients
showed a CI of 5 to 6 corresponding to that obtained with
fractions from plasma supplemented with 60 pg/ml of hu rIL-lJ3
(data not shown).
In these patients with the most pronounced IL-i activity, we
also verified that this activity was totally neutralized by anti-
IL-i, and in a dose-dependent manner (Table 1). Interestingly,
Table 1. Inhibition of plasma IL
against h
-1 activity by a polyclonal antibody
uman IL-l
Patient
Plasma ILia
(CI)
% Inhibitionb with anti IL-I
dilution of the antibody
1/25 1/50 1/100 1/200
1
2
3
4
4.2
4.5
5.9
6.2
90 82 89 75
86 73 79 70
79 63 76 35
85 86 45 21
hurlL-1/3
200 pg/ml
18.2 92 85 60 24
a Plasma LAF (IL-i) activity expressed as costimulation index (CI).b % inhibition: CI of plasma sample in the presence of the antibody
xIOO.CI of plasma sample in the presence of control serum
UR HD
Fig. 2. Plasma IL-i activity in 12 first-dialysis uremic (UR) and 24
long-term dialyzed (HD) patients at the start (T0) and the end (Tf) of a
single dialysis session. Plasma IL-I activity (CI) is measured as
described in legend of Figure 1. Each point represents the plasma IL-i
activity in a given patient. The differences observed between the s iii
and the end of the dialysis session in HD patients are significant (P <
0.001).
a similar neutralization pattern was obtained from fractionated
normal plasma supplemented with hu rIL-l/3.
Effect of the dialysis session. Figure 2 compares the plasma
LAF(IL- 1) activity at the start and at the end of a single dialysis
session in both first-dialyzed UR and long-term HD patients. In
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Fig. 3. Comparative effect of cellulosic-CUP membrane and synthetic-
PAN-AN 69 ,nembrane equipped dialyzer on plasma IL-I activity
during a single dialysis session in long-term dialyzed patients. Plasma
IL-i activity (CI) is measured as described in legend of Figure 1. Plasma
IL-i activity is significantly elevated in both CUP and PAN-AN 69
treated, long-term dialyzed patients compared to healthy control sub-
jects (P < 0.001) and in both groups further increased between the start
(Io) and the end (Tf) of the dialysis session (respectively P < 0.001 and
P < 0.005).
first-dialysis UR patients, the mean LAF(IL-l) activity re-
mained at its initial level, that is, similar to that observed in
normal subjects (Fig. 1). By contrast, in long-term HD patients,
the already high LAF(IL-l) activity observed at the start of the
dialysis session further increased in 18 out of 24 patients (P <
0.00 1).
As shown on Figure 3, which illustrates the influence of the
membrane equipping the dialyzer, HD patients routinely
treated with the cellulosic (CUP) dialysis membrane showed
higher predialysis levels of LAF(IL-1) plasma activity than
those with the synthetic (PAN-AN 69) membrane, but the
observed differences in the mean CI values (respectively 3.31
0.52 vs. 2.51 0.21, mean sEM) were not statistically
significant. At the end of the dialysis session, LAF(IL-l)
activity significantly increased in both CUP- (P < 0.001) and
PAN-AN 69- (P < 0.005) treated patients.
Plasma IL-I /3 immunoreactivitv
Table 2 shows results obtained when plasma IL-lJ3 level was
determined by its immunoreactivity in ELISA and RIA. Using
the ELISA, a significant increase in plasmatic IL-113 concentra-
tion was found in long-term HD patients as compared to its
almost undetectable level (<15 pglml according to the sensitiv-
ity of the assay) in first-dialysis UR patients (P < 0.05) and
control subjects (P < 0.03). In addition, this immunoreactive
IL- 1 activity increased during the dialysis session (P < 0.05),
thus corroborating the LAF assay determination. By contrast,
regardless of plasma origin and time of dialysis, no significant
IL-l/3 could be detected by RIA in any of the plasma tested.
This result confirms our previous observation that the LAF
assay is approximately ten times more sensitive than the RIA
specific for human IL- 1/3 (data not shown).
A strong linear correlation was observed (r =0.88,P <0.001,
N 31) when IL-I measured in the above experiments by
ELISA was compared to that obtained by the LAF assay in the
same plasma (Fig. 4).
Plasma TNFs immunoreactivity
Comparison between first dialysis and long-term dialysis
patients. Figure 5 illustrates the results obtained in the deter-
mination of plasma TNFa by radioimmunoassay in long-term
HD and first-dialysis UR patients before the dialysis session. It
is observed that: 1) compared to its level in normal subjects
(46.7 4.2 pg/mi, mean SuM), plasma TNFa immunoreac-
tivity was significantly higher in both long-term HD and first-
dialysis UR patients (P < 0.001); and 2) among the two groups
of patients, long-term HD had significantly higher TNFa levels
(131.8 5 pg/mI, mean SEM) than first-dialysis UR patients
(89.7 3.8 pg/ml, mean SEM, P < 0.00 1).
Effect of the dialysis session. As shown on Figure 6, RIA
determination of plasma TNFa levels before and at the end of
the dialysis session showed that TNFa remained constant, that
is, mean level comprised between 125 and 135 pg/mI in both
groups of patients. Moreover, regardless of the time of sam-
pling, plasma TNFa levels did not significantly differ between
the patients treated with CUP and those treated with PAN-AN
69 dialysis membranes (Fig. 7).
Plasma TNFa biological activity
To determine whether TNFa immunoreactivity in plasma
from dialyzed patients could exert biological activity, we tested
the capacity of some of these plasma to induce cytolytic activity
on the TNFa-sensitive L929 cell line.
Table 3 compares the TNFa activity measured in diluted
plasma from five long-term HD patients, four first-dialysis UR
patients and six normal subjects. No significant TNFa activity
could be detected in the plasma of normal subjects, except in
one case which showed TNFa level close to the detection limit
of the assay (10 TNFa U/mi). Compared to normal subjects,
significant TNFa activity was detected before the dialysis
session in three out of four first-dialysis UR patients and four
out of five long-term HD patients. Plasma TNFa activity was
also significantly higher in long-term HD patients than in
first-dialysis UR patients, although in both groups it remained
constant between the start and the end of the dialysis session.
IFNy and IL-2 determinations
Neither immunoreactive IFNy nor IL-2, determined either by
the IL-2 CTLL-dependent assay or by RIA, was detected in any
of the plasma from UR (N = 14) or long-term HD (N = 16)
patients.
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Table 2. IL-l/3 immunoreactivity in patients before and after hemodialysis
Controls
First-dialysis UR patients Long-term HD patients
Before After Before After
ELISA 7.60 4,82 12.50 5.95 13.15 5.05 31.15 5.05 51.15 12.70
pg/mi (5) (6) (6) (7) (7)
RIA NDb ND ND ND ND
pg/mi (5) (6) (6) (7) (7)
Plasma immunoreactive IL-l/3 levels are expressed in pg/mi (mean sEM). Compared to the basal levels in normal subjects (P < 0.03) and
pre-dialysis levels in first-dialysis UR patients (P < 0.05), pre-dialysis levels are significantly elevated in long-term HD patients and further
increased during HD (P < 0.05).
a Number of cases in each group testedb Not detectable, that is, below 250 pg/mi
Discussion
The present study shows that both IL-i and TNFa are
significantly increased in the plasma of long-term hemodialysis
patients whereas in first-dialysis UR patients, TNFa, but not
IL-l, is detected in the plasma. In both first and long-term
dialysis patients, neither IFNy nor IL-2 can be detected. Since
IL-i and TNFa are mainly of monocyte origin, whereas IFNy
and IL-2 are lymphocyte products, these findings strongly
support the hypothesis of selective monocyte activation in-
duced in both first- and long-term dialysis patients.
Indirect evidence for the presence of circulating IL- 1 in
long-term HD patients had also recently been afforded by
studies showing that increased intracellular IL- 1 activity can be
observed in freshly isolated monocytes [44] and in supernatants
of unstimulated peripheral blood mononuclear cells isolated
from long-term HD patients [10]. Previous studies of plasma
LAF(IL-l) activity, recently reported by several groups includ-
ing ours [8—10] involved a limited number of long-term HD
patients and did not investigate the presence of this monokine in
UR nondialyzed patients.
The present study, based on a large series of 44 patients,
provides strong evidence that significant LAF(IL- 1) plasma
activity is detectable in long-term HD patients and also first
shows that it is not exclusively related to uremia. Moreover, we
formally established that IL-i is responsible for the observed
LAF activity: indeed, this activity elutes predominantly in the
12,000 to 18,000 molecular wt range, corresponding to the
C UR HO
Fig. 5. Plasma immunoreactive TNFa levels (pg/mi) in 21 healthy
control subjects (C), 18 first-dialysis uremic (UR) and 16 long-term
dialyzed (HD) patients before a dialysis session. Each point represents
the mean of duplicate determination. TNFa levels are significantly
elevated in both UR and long-term HD patients compared to C subjects
(P < 0.001), and significantly elevated in long-term HD patients
compared to first-dialysis UR patients (P < 0.001).
known molecular wt of IL- 1; it is neutralized by a polyclonal
anti-IL-l antibody; lastly, a close correlation exists between
LAF activity and the level of immunoreactive IL- 1 as measured
by ELISA. The presence of circulating IL-i measured by
immunoreactivity has not yet been reported in long-term HD
patients. Although immunoreactive IL-i was detected by
ELISA, it could not be detected by RIA, which is ten times less
sensitive.
Other cytokines can likewise be present in the plasma of
these patients and more particularly IL-6, which is active in the
PHA-induced thymocyte assay [37]. Although IL-6 was not
specifically tested in the present study, the fact that hu rIL-6
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Fig. 4. Correlation between measurements of IL-I by LAF bioassay(CI) and ELISA (pg/mi) in plasma from 5 control subjects, 6 first-
dialysis UR and 7 long-term HD patients before and after the dialysis
session (r 0.88, P < 0.001, N = 31).
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UR HD
Fig. 6. Plasma immunoreactive TNFa levels (pg/mi) in 14 first-dialysis
uremic (UR) and 14 long-term dialyzed (HD) patients at the start (T0)
and the end (1') of dialysis session. Each point represents the mean of
duplicate determination, TNFa levels are not significantly different at
the end of dialysis compared to its level at the start in both UR and HD
patients.
induced no significant thymocyte proliferation at the PHA
concentration used in our LAF assay argues against the possi-
bility that it could interfere in the IL-i bioassay. Moreover, we
could exclude the presence of IL-2, which is also known to
interfere in the LAF assay, and the possibility that human IL-4
could induce significant proliferation of murine thymocytes.
The presence of plasma TNFa, a cytokine intimately associ-
ated with the acute phase response and sharing almost all of its
properties with IL-i, has recently been reported in one long-
term HD patient by Lonnemann et al [18]. The present study
shows that TNFa is considerably increased in plasma of long-
term HD patients compared to normal subjects. Unlike IL-l,
TNFa is also significantly increased in UR patients before their
first dialysis, although not as much as in long-term HD patients.
This apparent discrepancy between IL-i and TNFa plasma
levels observed in uremic patients suggests that uremia-depen-
dent factors may selectively influence the secretion of TNFa
without interfering with that of IL-i. Alternatively, one may
propose that these factors induce the production of both
monokines but that while the former is secreted, the latter
remains intracellular and/or membrane-associated. Previous
studies have reported the presence of such a form of IL-i,
especially in long-term HD patients [44]. By contrast, no
I L
To Tf To Tf
CUP PAN
Fig. 7. Comparative effect of celiulosic-CUP and synthetic-PAN-AN
69 membrane-equipped dialyzers on plasma immunoreactive TNFa
levels (pg/mi) during a single dialysis session in long-term dialyzed
(HD) patients. Each point represents the mean of duplicate determina-
tions. TNFa levels are not significantly different in CUP compared to
PAN-AN 69 treated HD patients. No significant change in TNFa levels
is observed at the end (Tf) compared to the start (T0) of dialysis session
regardless of the type of membrane equipping the dialyzer.
Table 3. TNFa activity in patients before and after hemodialysis
First-dialysis UR Long-term HD
Controls
patients patients
Before After Before After
7.05 3.58 39 14.8 35 12.6 60 28.3 76 24
(6) (4) (4) (5) (5)
Plasma TNFa activity is expressed in units/mi (mean 5EM).
Compared to the basal levels in normal subjects, pre-dialysis levels are
significantly elevated both in first-dialysis UR (P < 0.02) and long-term
HD (P < 0.05) patients, but not further increased during HD in both
groups of patients.a Number of cases in each group tested.
evidence for cell-associated TNFcr has been reported; in addi-
tion, we failed to detect its presence in LPS stimulated human
monocytes (unpublished observations).
Increased TNFa levels in the plasma of not yet dialyzed UR
patients could be induced by damaged cells. Baud et al [45]
recently showed that rat mesangial cells produce cytokines
related to TNFa. Similar observations were also reported by
other groups with rat [46] or rabbit [47] glomeruli. These
findings suggest that mesangial cells could be responsible for
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the increased TNFa production observed in patients with
end-stage renal failure. Alternatively, a possible role of in-
creased TNFa levels in the development of renal impairment
before dialysis should be considered. In fact, some authors
have recently shown that TNFa infused in rats can induce
metabolic acidosis and acute renal failure [3]. Moreover, Rhee,
McGoldnck and Meuwissen [271 reported the presence of a
neutrophil stimulatory reduced oxygen species (ROS) factor in
serum from nondialyzed UR patients and suggested that it is
specifically associated with renal dysfunction. Although this
serum factor was found in the range of 1,000 dalton molecular
mass, the role of TNFa, known to induce ROS production by
phagocytic cells [48], remains to be investigated in nondialyzed
UR patients. Progressive renal damage may indeed result from
TNFa-induced production of ROS by neutrophils in the vascu-
lar membrane of the kidney.
Interestingly, during the first dialysis session, IL- 1 remained
undetectable and TNFa maintained its initial level. These
findings may suggest that repeated dialysis sessions and/or
accumulation of dialysis-related factors are necessary to induce
or to amplify the secretion of these cytokines. Comparative
investigation of TNFa and IL-i plasma levels at the beginning
and the end of a single dialysis session in long-term HD patients
showed a significant increase in IL-l but not in TNFa. This
discrepancy between the evolution of IL-i and TNFa levels
could be explained by differences in the kinetics of secretion of
the two monokines. In this regard, Michie et a! [49] have
reported that TNFa response following injection of endotoxin
in human volunteers occurs between the 90th and 120th minute
and is no longer detected at the 4th hour.
In contrast to our previous report showing that CUP but not
PAN-AN 69 membrane induces a significant activation of
phagocyte oxidative metabolism [311, we did not detect a major
influence of CUP membrane on IL-l or TNFa secretion. Since
CUP but not PAN-AN 69 membrane has the potential of
activating the complement system, our observations suggest
that IL-i and TNFa production in long-term HD patients is not
exclusively caused by the activation complement fragments
which are well known to be potent inducers of both IL-i and
TNFa secretion [50—52]. Interestingly, Binge! et al [531 recently
reported that long-term HD patients treated with CUP mem-
branes display high plasma levels of IL-l activity but that this
was markedly decreased upon a subsequent dialysis with PAN
membrane, thus suggesting that this membrane might favor the
binding or the clearance of IL- 1. The discrepancy between that
study and ours remains to be explained. However, the fact that
our patients were treated for at least three months with CUP or
PAN membrane, allows a more accurate appreciation of the
proper effect of each of the two membranes. Lastly, Haeffner-
Cavaillon et a! [44], measuring intramonocytic IL-! activity,
also found that both CUP- and PAN-treated patients display
increased IL-l activity and that no significant difference could
be detected between the two groups of patients.
In vitro, Betz et al [32] have shown that a complement
independent stimulation of IL-i release by human monocytes
may occur following a brief exposure to cuprammonium dialy-
sis membranes. Concerning the synthetic (PAN) dialysis mem-
brane, Lonnemann et al [54] have reported its intrinsic property
to stimulate IL-i production. Since circulating IL-i and/or
TNFa are present in first-dialysis UR and long-term HD pa-
tients regardless of the type of the membrane equipping the
dialyzer, and given the above-mentioned in vitro studies, we
conclude that the type of membrane does not exert a pivotal
role on the presence of these circulating cytokines.
Among other factors which may contribute to triggering the
secretion of these monokines in hemodialysis patients and
consequently to masking complement-dependent monokine
production, the microbial contamination of the dialysate should
be considered. Although all the evidence is not yet in hand, it is
highly probable that repeated exposure of blood to minimal
doses of endotoxin may lead to chronic monocyte activation. In
addition, according to a recent report from Nisbeth et a! [55],
significant amounts of circulating endotoxins can be present in
not yet dialyzed UR patients, thus suggesting a possible role of
LPS in the increased levels of TNFa observed at the beginning
of the first dialysis. The fact that IL-i was not detectable in
these patients could be related to a recent report [49] showing
increased plasma TNFa but not IL-i in normal subjects treated
with endotoxins.
Even though we show that IL- 1 and TNFa can be detected in
plasma of long-term HD patients, it remains to be verified
whether these two monokines are present in sufficient amounts
to be responsible for the clinical manifestations seen in long-
term dialysis patients. Concerning IL-i, this study provides
evidence for the presence of circulating immunoreactive IL-i in
long-term HD patients, thus corroborating previous [8] and
present findings obtained by the LAF assay. However, the IL-i
levels observed, ranging between 30 and 60 pg/mI (except in one
case in which it rose over 100 pg/mi), are much lower than those
reported by Maury and Teppo [56] in renal allograft recipients
undergoing acute rejection. Concerning TNFa, recent studies
have demonstrated elevated levels of plasma TNFa in infec-
tious diseases. Scuderi et al [57], using an enzyme immunoas-
say, found a mean level of TNFa reaching 119 pg/ml in patients
with malaria, while Waage, Halstensen and Espevik [19], using
a bioassay, found raised TNFa levels (440 U/mI corresponding
to 100 pg/mI) in septicemic patients. The fact that in our study,
on the one hand, similar immunoreactive TNFc levels are
found in the plasma from long-term HD patients and, on the
other hand, that this TNFs is biologically active, favors the
hypothesis that TNFa could be at least partly implicated in the
clinical manifestations observed in these patients.
Moreover, particular attention must be paid to synergistic
properties of TNFa and IL-l monokines. Recent studies sup-
port the concept that IL-! and TNFa act synergistically in a
variety of biological processes such as fibroblast prostaglandin
E2 production [58] and induction of polymorphonuclear leuko-
cyte migration [161. Furthermore, the possibility that plasma
TNFa when present at sufficient levels could itself induce IL-l
secretion by monocytes [15], must also be considered in long-
term HD patients. In this regard, recent results in the study of
the hypotensive effect of IL-l and TNFa in rabbits are relevant
to the synergy resulting from the combination of TNFa itself
plus IL-i induced by TNFa in these rabbits [12]. Similarly, the
participation of IL-6 which has been shown to be involved in
the acute phase response [59] and to be produced by monocytes
in response to TNFa or IL-I [60, 61], requires further study.
Furthermore, endotoxin contaminants entering the blood com-
partment from the dialysate may not only induce monokine
production but also act as a potentiator of several monokine
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functions. Likewise, strong synergy between TNFa and bacte-
ria and their products, causing hemorrhagic necrosis and lethal
shock in normal mice, has been recently described [62].
In conclusion, the present study supports the hypothesis that
both dialysis and uremia related factors contribute to monocyte
activation and consequent IL-i and/or TNFa production. The
multifaceted biological effects of monokines, which we showed
to be produced in large amounts during HD treatment, may
explain some of the pathological findings observed in these
patients. In addition, our findings demonstrate that the release
of IL-i and TNFa into the circulation in man is not confined to
severe bacterial infections, but also occurs in the immunologi-
cal tissue injury caused by the inflammatory response. Lastly, it
is tempting to propose that long-term production of these two
monokines, which are known for their synergistic effects, may
account for the occurrence of acute phase changes in HD
patients.
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